[1]樊福强,周华祥,郭学廷.血管性痴呆患者血清AIM2 和载脂蛋白J 水平表达与临床病情程度评估及预后的关系研究[J].现代检验医学杂志,2024,39(03):109-114.[doi:10.3969/j.issn.1671-7414.2024.03.018]
　FAN Fuqiang,ZHOU Huaxiang,GUO Xueting.Relationship between the Levels of Serum AIM2 and Apolipoprotein J and Clinical Severity in Patients with Vascular Dementia and Their Prognosis[J].Journal of Modern Laboratory Medicine,2024,39(03):109-114.[doi:10.3969/j.issn.1671-7414.2024.03.018]
点击复制

血管性痴呆患者血清AIM2 和载脂蛋白J 水平表达与临床病情程度评估及预后的关系研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第39卷
期数:
2024年03期
页码:
109-114
栏目:
论著
出版日期:
2024-05-15

文章信息/Info

Title:
Relationship between the Levels of Serum AIM2 and Apolipoprotein J and Clinical Severity in Patients with Vascular Dementia and Their Prognosis
文章编号:
1671-7414（2024）03-109-06
作者:
樊福强; 周华祥; 郭学廷
（滨州市第二人民医院神经内科，山东滨州 256800）
Author(s):
FAN Fuqiang; ZHOU Huaxiang; GUO Xueting
（Department of Neurology, the Second People’s Hospital of Binzhou, Shandong Binzhou 256800, China）
关键词:
黑色素瘤缺乏因子2; 载脂蛋白J; 血管性痴呆; 病情程度
分类号:
R749.13；R446.11
DOI:
10.3969/j.issn.1671-7414.2024.03.018
文献标志码:
A
摘要:
目的 探究血管性痴呆（vascular dementia, VD）患者血清黑色素瘤缺乏因子2（absent in melanoma 2，AIM2）、载脂蛋白J（apolipoprotein J，Apo J）水平与病情程度及预后的关系。方法 选取滨州市第二人民医院2020 年10 月～ 2022 年9 月接诊的血管性痴呆患者128 例作为研究组，依据简易精神状态检查表（mini-mental stateexamination，MMSE）评分评估病情严重程度，将研究组分为轻度组（n=43）、中度组（n=54）和重度组（n=31）；治疗90 天后根据日常生活能力（activities of daily living，ADL）量表评分评估患者预后，分为Ⅰ级组（n=66）、Ⅱ级组（n=40）和Ⅲ级组（n=22）；另选取同期正常健康体检者96 例作为对照组。应用实时荧光定量PCR(qRT-PCR)、酶联免疫吸附测定(ELISA) 法检测血清AIM2 和Apo J 表达水平，并进行各组间比较；采用Spearman 法分析血清AIM2，Apo J 表达水平与MMSE 评分的相关性以及与预后的关系；采用Logistic 回归分析血管性痴呆患者预后影响因素。结果 与对照组比较，研究组血清AIM2 mRNA（3.11 ± 0.57 vs 1.06 ± 0.23）表达水平显著升高，血清Apo J 表达水平显著降低（68.83 ± 12.24 ng/L vs 81.07 ± 13.15 ng/L），差异具有统计学意义（t=32.054，7.174，均P ＜ 0.001）；重度组血清AIM2 mRNA 表达水平显著高于轻度组和中度组（q=12.807，15.780），血清Apo J 表达水平、MMSE 评分均明显低于轻度组和中度组（q=26.021，4.301；12.191，20.802），且中度组血清AIM2 mRNA 表达水平显著高于轻度组（q=14.688），血清ApoJ 表达水平、MMSE评分均低于轻度组（q=20.338，37.537），差异具有统计学意义（均P ＜ 0.001）；血管性痴呆患者Ⅲ级组血清AIM2 mRNA（5.27 ± 0.60）表达水平显著高于Ⅱ级组（3.36 ± 0.58）、Ⅰ级组（2.23 ±0.55），而血清ApoJ（51.22 ± 12.21 ng/L）表达水平显著低于Ⅱ级组（64.15 ± 12.23 ng/L）、Ⅰ级组（77.53 ± 12.25ng/L）；Ⅱ级组血清AIM2 mRNA 表达水平显著高于Ⅰ级组，而血清ApoJ 表达水平显著低于Ⅰ级组，差异具有统计学意义（q=5.630~30.740，均P ＜ 0.001）；血管性痴呆患者血清AIM2 水平与MMSE 评分呈负相关性，与预后（ADL 分级）呈正相关性（r=-0.535，0.432，均P ＜ 0.001）；血管性痴呆患者血清ApoJ 水平与MMSE 评分呈正相关性，与预后（ADL 分级）呈负相关性（r=0.467，-0.496，均P ＜ 0.001）；血清AIM2 mRNA[OR(95%CI)：2.746(1.481 ～ 5.091)，Apo J[OR(95%CI)：0.496(0.311 ～ 0.791)，MMSE 评分[OR(95%CI)：0.568(0.347 ～ 0.931) 为血管性痴呆患者预后的影响因素（均P ＜ 0.05）。结论 血管性痴呆患者血清AIM2 mRNA 表达水平升高，血清Apo J 表达水平降低，与患者病情程度及预后密切相关，可有效评估患者预后。
Abstract:
Objective To explore the relationship between the serum levels of absent in melanoma 2 (AIM2) and apolipoprotein J (Apo J) and the severity and prognosis of vascular dementia(VD). Methods From October 2020 to September 2022, 128 patients with vascular dementia were collected as the study group in the Second People’s Hospital of Binzhou.Based on the minimental state examination (MMSE) score, the severity of the condition was evaluated and the study group was separated into mild group(n=43), moderate group(n=54) and severe group(n=31). After 90 days of treatment, the prognosis of patients was evaluated based on the ability of daily living (ADL) scale score and grouped into grade I group(n=66), grade II group(n=40) and grade III group(n=22). Another 96 healthy individuals who underwent physical examination were selected as the control group. The expression levels of serum AIM2 and Apo J were detected by qRT-PCR and ELISA methods, and the differences between the groups were compared. Spearman method was applied to analyze the correlation between serum AIM2 and ApoJ expression levels and MMSE scores, and the relationship between serum AIM2 and Apo J expression levels and prognosis in patients with vascular dementia. Logistic regression was applied to analyze the prognostic factors of vascular dementia patients. Results The expression level of serum AIM2 mRNA (3.11 ± 0.57 vs 1.06 ± 0.23) in the study group was higher than those in the control group, while the expression level of serum ApoJ (68.83 ± 12.24 ng/L vs 81.07 ± 13.15 ng/L) was lower than that in the control group, with significant differences (t=32.054, 7.174, all P<0.001). The expression level of serum AIM2 mRNA in the severe group was higher than that in the mild and moderate groups (q=12.807, 15.780), the expression level of serum Apo J and MMSE score in the severe group were lower than those in the mild and moderate groups (q=26.201, 4.301; 12.193, 20.802)，the expression level of serum AIM2 mRNA in the moderate group was higher than that in the mild group (q=14.688), and the expression level of serum Apo J and MMSE score in the moderate group were lower than those in the mild group (q=20.338, 37.537), with significant differences (all P<0.001). The expression level of serum AIM2 mRNA (5.27 ± 0.60) in the grade III group of vascular dementia was higher than that in the grade II (3.36 ± 0.58) and grade I groups (2.23 ± 0.55), while the expression level of serum Apo J (51.22 ± 12.21 ng/L) was lower than that in the grade II (64.15 ± 12.23 ng/L) and grade I groups (77.53 ± 12.25 ng/L). The expression level of serum AIM2 mRNA in the grade II group was higher than that in the grade I group, while the expression level of serum Apo J in the grade II group was lower than that in the grade I group, with significant differences (q=5.630~30.740, all P<0.001). The level of serum AIM2 in patients with vascular dementia was negatively correlated with MMSE score but positively correlated with prognosis (ADL grade) （r=-0.535，0.432，all P ＜ 0.001）, while the level of serum Apo J in patients with vascular dementia was positively correlated with MMSE score but negatively correlated with prognosis (ADL grade) （r=0.467，-0.496，all P ＜ 0.001）. Serum AIM2 mRNA [OR(95%CI): 2.746(1.481 ～ 5.091)], Apo J [OR(95%CI): 0.496(0.311 ～ 0.791)], and MMSE score [OR(95%CI): 0.568(0.347 ～ 0.931)] were influencing factors for the prognosis of vascular dementia patients (all P<0.05). Conclusion The increase of serum AIM2 mRNA expression level and the decrease of serum Apo J expression level in patients with vascular dementia were closely related to the clinical severity and prognosis of patients, which may effectively evaluate the prognosis of patients.

参考文献/References:

[1] BIR S C, KHAN M W, JAVALKAR V, et al. Emerging concepts in vascular dementia: a review[J]. Journal of Stroke and Cerebrovascular Diseases, 2021, 30(8):105864.
[2] T I A N Z h e n g m i n g , J I X u n m i n g , L I U J i a . Neuroinflammation in vascular cognitive impairment and dementia: current evidence, advances, and prospects[J]. International Journal of Molecular Sciences, 2022, 23(11): 6224.
[3] SHARMA B R, KARKI R, KANNEGANTI T D. Role of AIM2 inflammasome in inflammatory diseases, cancer and infection[J]. European Journal of Immunology, 2019, 49(11): 1998-2011.
[4] DU Luping, WANG Xuyang, CHEN Siyuan, et al. The AIM2 inflammasome: A novel biomarker and target in cardiovascular disease[J]. Pharmacological Research,2022, 186: 106533.
[5] FIDLER T P, XUE Chenyi, YALCINKAYA M, et al. The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis[J]. Nature, 2021, 592(7853):296-301.
[6] CHENG Hongxia, WANG Sikai, HUANG Aidan, et al. HSF1 is involved in immunotherapeutic response through regulating APOJ/STAT3-mediated PD-L1 expression in hepatocellular carcinoma[J]. Cancer Biology & Therapy, 2023, 24(1): 1-9.
[7] RIVAS-URBINA A, RULL A, ALDANA-RAMOS J,et al. Subcutaneous administration of apolipoprotein J-Derived mimetic peptide d-[113-122]Apo J improves LDL and HDL function and prevents atherosclerosis in LDLR-KO mice[J]. Biomolecules, 2020, 10(6): 829.
[8] 中华医学会神经病学分会. 血管性痴呆诊断标准草案[J]. 中华神经科杂志, 2002, 35(4): 246. Chinese Society of Neurology, Chinese Medical Association. Draft of diagnostic criteria for vascular dementia[J]. Chinese Journal of Neurology, 2002,35(4): 246.
[9] 吉宏明, 胡昌辰, 张刚利, 等. 简易精神状态检查表在胶质瘤患者认知功能评价中的初步应用[J]. 肿瘤研究与临床, 2012, 24(5): 311-312, 315. JI Hongming, HU Changchen, ZHANG Gangli, et al. Preliminary application of MMSE cognitive assessment in the patients with glioma[J]. Cancer Research and Clinic, 2012, 24(5): 311-312, 315.
[10] HOBERT M A, HOFMANN W, BARTSH T, et al. Vaskul?r bedingte Demenzen erkennen und behandeln [Diagnosis and treatment of vascular dementia][J].Zeitschrift fur Gerontologie und Geriatrie, 2020,53(7):687-698.
[11] JIANG Pan, CHEN Lei, SUN Jing, et al. Chotosan ameliorates cognitive impairment and hippocampus neuronal loss in experimental vascular dementia via activating the Nrf2-mediated antioxidant pathway[J].Journal of Pharmacological Sciences, 2019, 139(2):105-111.
[12] WANG Liqiu, LIU Tao, YANG Shuai, et al. Author correction: Perfluoroalkyl substance pollutants activate the innate immune system through the AIM2 inflammasome[J]. Nature Communications, 2022,13(1): 5667.
[13] 刘懿, 贺晓婵, 王亚荣, 等. 急性缺血性脑卒中患者血清AIM2 和LTB4 水平表达及与预后的相关性研究[J]. 现代检验医学杂志, 2023, 38(4): 22-26, 172. LIU Yi, HE Xiaochan, WANG Yarong, et al. Study on the expression levels of serum AIM2 and LTB4 in patients with acute ischemic stroke and their correlation with prognosis[J]. Journal of Modern Laboratory Medicine, 2023, 38(4): 22-26, 172.
[14] FUKUDA K, OKAMURA K, RIDING R L, et al. AIM2 regulates anti-tumor immunity and is a viable therapeutic target for melanoma[J]. Journal of Experimental Medicine, 2021, 218(9): e20200962.
[15] ZHOU Zheng, LI Cong, BAO Tianyi, et al. Exosomeshuttled miR-672-5p from anti-inflammatory microglia repair traumatic spinal cord injury by inhibiting AIM2/ASC/caspase-1 signaling pathway mediated neuronal pyroptosis[J]. Journal of Neurotrauma, 2022, 39(15/16):1057-1074.
[16] POH L, RAZAK S M B A, LIM H M, et al. AIM2 inflammasome mediates apoptotic and pyroptotic death in the cerebellum following chronic hypoperfusion[J].Experimental Neurology, 2021, 346: 113856.
[17] KO Y A, BILLHEIMER J T, LYSSENKO N N, et al. ApoJ/clusterin concentrations are determinants of cerebrospinal fluid cholesterol efflux capacity and reduced levels are associated with Alzheimer’s disease[J]. Alzheimer’s Research & Therapy, 2022,14(1): 194.
[18] MIRON J, PICARD C, LABONT? A, et al. MSR1 and NEP are correlated with Alzheimer’s disease amyloid pathology and apolipoprotein alterations[J]. Journal of Alzheimer’s Disease, 2022, 86(1): 283-296.
[19] 楚长彪, 蔡慧敏, 贾龙飞. 血浆载脂蛋白J 对阿尔茨海默病的诊断价值[J]. 中国医刊, 2023, 58(7): 719-722. CHU Changbiao, CAI Huimin, JIA Longfei. The diagnostic value of plasma apolipoprotein J for Alzheimer’s disease[J]. Chinese Journal of Medicine,2023, 58(7): 719-722.

相似文献/References:

[1]刘 懿,贺晓婵,王亚荣,等.急性缺血性脑卒中患者血清AIM2 和LTB4 水平表达及与预后的相关性研究[J].现代检验医学杂志,2023,38(04):22.[doi:10.3969/j.issn.1671-7414.2023.04.004]
　LIU Yi,HE Xiaochan,WANG Yarong,et al.Study on the Expression Levels of Serum AIM2 and LTB4 in Patients with Acute Ischemic Stroke and Their Correlation with Prognosis[J].Journal of Modern Laboratory Medicine,2023,38(03):22.[doi:10.3969/j.issn.1671-7414.2023.04.004]

备注/Memo

备注/Memo:
作者简介： 樊福强（1982-），男，硕士研究生，主治医师，研究方向：缺血性脑血管疾病的规范化诊治及介入治疗，E-mail：tlw50y@163.com。
通讯作者： 周华祥（1977-），男，硕士研究生，副主任医师，研究方向：缺血性脑血管疾病的规范化诊治及介入治疗，E-mail：fanfuqiang2008@163.com。
更新日期/Last Update: 2024-05-15